Skip to main content
SpringerLink
Log in

FIRE-7-Studie (AIO-KRK-0120)

Virtuelle, zentrale, interdisziplinäre Tumorkonferenz zur Verbesserung der sekundären Interventionsrate in mKRK-Patienten mit RAS-Mutation unter Therapie mit FOLFOXIRI und Bevacizumab

The FIRE-7 trial (AIO-KRK-0120)

Virtual, central, interdisciplinary tumor conference on improvement of the rate of secondary intervention in mCRC patients with a RAS mutation receiving FOLFOXIRI and bevacizumab

  • Sektion B - Klinische Studien
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315

    Article  CAS  Google Scholar 

  2. De Haas RJ, Wicherts DA, Flores E et al (2008) R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 248:626–637

    Article  Google Scholar 

  3. Folprecht G, Gruenberger T, Bechstein W et al (2014) Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25:1018–1025

    Article  CAS  Google Scholar 

  4. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

    Article  CAS  Google Scholar 

  5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe Awmf): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL.

  6. Modest DP, Denecke T, Pratschke J et al (2018) Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE‑3. Eur J Cancer 88:77–86

    Article  CAS  Google Scholar 

  7. Modest DP, Heinemann V, Folprecht G et al (2020) Factors that influence conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): analysis of FIRE-3-AIOKRK0306. Ann Surg Oncol 27:2389–2401

    Article  Google Scholar 

  8. Modest DP, Ricard I, Heinemann V et al (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27:1746–1753

    Article  CAS  Google Scholar 

  9. National Comprehensive Cancer Network (2020) Clinical practice guidelines in oncology (NCCN Guidelines) colon cancer version 4.2020

    Google Scholar 

  10. Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Deutschland

    Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, Jobst Christian von Einem & Ivan Jelas

  2. Medizinische Klinik und Poliklinik III, Klinikum der Universität München, München, Deutschland

    Kathrin Heinrich, Julian Walter Holch & Volker Heinemann

  3. Chirurgische Klinik und Poliklinik, Klinikum der Universität München, München, Deutschland

    Jan D’Haese & Martin Angele

  4. Chirurgische Klinik, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Deutschland

    Johann Pratschke & Wenzel Schöning

  5. Klinik und Poliklinik für Radiologie, Klinikum der Universität München, München, Deutschland

    Wolfgang Kunz & Florian Streitparth

  6. Klinik für Radiologie, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Deutschland

    Bernhard Gebauer

  7. Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der Universität München, München, Deutschland

    Stefanie Corradini

  8. Klinik für Radioonkologie und Strahlentherapie, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Deutschland

    Carmen Stromberger

Authors
  1. Arndt Stahler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dominik Paul Modest
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Stintzing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jobst Christian von Einem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ivan Jelas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kathrin Heinrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julian Walter Holch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan D’Haese
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martin Angele
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Johann Pratschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wenzel Schöning
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wolfgang Kunz
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Florian Streitparth
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Bernhard Gebauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Stefanie Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Carmen Stromberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Volker Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arndt Stahler.

Ethics declarations

Interessenkonflikt

A. Stahler erhielt Honorare aus Referententätigkeit von Roche sowie Reisekostenerstattungen von Roche, Merck KGaA, MSD Sharp & Dohme und Amgen. D. P. Modest, S. Stintzing und V. Heinemann erhielten Honorare für Referenten- und Beratertätigkeit sowie Reisekostenerstattungen von folgenden Firmen: Merck KGaA, Amgen, Roche, Takeda, Servier, Pierre Fabre, Taiho, Lilly Oncology, Servier, Sanofi-Aventis, Bayer Pharmaceuticals. J. C. von Einem, I. Jelas, K. Heinrich, J. W. Holch, J. D’Haese, M. Angele, J. Pratschke, W. Schöning, W. Kunz, F. Streitparth, B. Gebauer, S. Corradini und C. Stromberger geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stahler, A., Modest, D.P., Stintzing, S. et al. FIRE-7-Studie (AIO-KRK-0120). Forum 36, 244–246 (2021). https://doi.org/10.1007/s12312-021-00923-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-021-00923-2

Search

Navigation